

Journal Pre-proof

The role of IgG subclasses and platelets in experimental anaphylaxis

Ophelie Godon, Msc, Beatrice Hechler, PhD, Friederike Jönsson, PhD

PII: S0091-6749(21)00089-0

DOI: <https://doi.org/10.1016/j.jaci.2021.01.009>

Reference: YMAI 14938

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 28 August 2020


Revised Date: 11 January 2021

Accepted Date: 18 January 2021

Please cite this article as: Godon O, Hechler B, Jönsson F, The role of IgG subclasses and platelets in experimental anaphylaxis, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2021.01.009>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.



Cognitive/Behaviour

- Inactivity
- Drop in core temperature
- Unresponsiveness
- Unconsciousness

Respiratory

- Angioedema
- Reduced respiratory frequency
- Restricted tidal volume
- Hypoxia

Digestive


- Diarrhea

Cardiovascular

- Hypotension
- Tachycardia
- Vasodilatation
- Increased vascular permeability
- Syncope

Skin

- Redness
- Edema



The role of IgG subclasses and platelets in experimental anaphylaxis

Ophelie Godon, Msc^{1,*}, Beatrice Hechler, PhD^{2,*} and Friederike Jönsson, PhD¹

¹ Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.

² INSERM UMR_S1255, Etablissement Français du Sang (EFS) Grand Est, 67065 Strasbourg, France

* equal contribution

Conflict of Interest Statement

The authors declare no conflict of interest.

Correspondence:

Friederike Jönsson
Unit of Antibodies in Therapy and Pathology,
Institut Pasteur,
UMR1222 INSERM,
25, rue du Docteur Roux
75015 Paris, France.
Tel. +33-(0)1-40-61-35-45
joensson@pasteur.fr

Keywords (5): Experimental anaphylaxis; Mouse model; IgG subclasses; Platelets; FcγRs

47

48 **Introduction**

49 In 1902, Charles Richet coined the term “anaphylaxis” to describe a “state of
50 heightened sensitivity of a subject to a substance induced by a first injection, that instead of
51 protecting the organism, renders it more fragile and more susceptible”. Since this first
52 description, experimental work led to identification of antibodies, receptors, cells and
53 mediators in this severe allergic reaction, leading to the paradigm that anaphylaxis is an IgE-
54 dependent affliction that is triggered when allergens aggregate cognate IgE antibodies bound
55 to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. Their
56 activation leads to the release of diverse bioactive mediators, including histamine, which are
57 responsible for the associated clinical signs (1). Seminal works from the Galli, Kinet and
58 Finkelman labs revealed, however, that anaphylaxis can also occur in mice deficient for IgE,
59 FcεRI or mast cells, and suggested that it could be driven by IgG antibodies engaging Fcγ-
60 chain containing receptors (reviewed in (1)). Nowadays the international consensus on
61 anaphylaxis defines anaphylaxis as “a serious, generalized or systemic, allergic or
62 hypersensitivity reaction that can be life-threatening or fatal”, which is deliberately generic
63 and excludes any precision on the pathophysiological mechanism involved.

64 In this manuscript we will discuss recent findings on IgG-dependent anaphylaxis with
65 a focus on the role of IgG subclasses and platelets in these reactions.

66

67 **IgG-dependent anaphylaxis in wild-type mice**

68 IgG-dependent passive systemic anaphylaxis (IgG-PSA) can be elicited in mice by the
69 transfer of specific IgG antibodies (of either IgG1, IgG2a/c or IgG2b subclass, but not IgG3)
70 followed by injection of their cognate antigen, or by transfer of pre-complexed IgG (*i.e.*
71 immune complexes (IgG-ICs) or heat-aggregated IgG). IgG-PSA depends on IgG receptor
72 (FcγR)-transduced activation of myeloid cells, leading to mediator release, which notably
73 include platelet-activating factor (PAF) (1, 2). Mice express three activating (FcγRI, FcγRIII
74 and FcγRIV) and one inhibitory FcγRs (FcγRIIB) each having a specific expression profile
75 and distinct affinities for the different IgG subclasses. IgG-PSA in mice is associated with
76 vasodilation, augmented vascular permeability and a reduction in core temperature, motility
77 and awareness (Figure 1). Animals usually return to normal activity and behavior within 1-2
78 hours, but in rare cases cardiopulmonary failure results in death. (IgG)-anaphylaxis can also
79 be triggered by antigen exposure of previously immunized mice that lack key players of the

IgE-dependent pathway. IgG-independent immune players may however contribute to the reaction, rendering the interpretation of results more complex. To efficiently engage activating IgG receptors, IgG generally need to be present as multivalent complexes. There is a large consensus that IgG-PSA relies mainly on the engagement of FcγRIII and, to a lesser extent, on FcγRIV and possibly on FcγRI (2, 3).

The relative importance of FcγR-bearing effector cells to IgG-PSA remains more debated and is likely to depend on the experimental conditions (1-3). Indeed, all cells of hematopoietic origin express at least one activating FcγR with the exception of T cells, B cells and platelets, and could hence contribute to the reaction. Their involvement in anaphylaxis is often assessed either using depleting antibodies, which is problematic in the context of an antibody-dependent reaction, or using inhibitors, which may not be specific. In a comparative study using mouse IgG1, IgG2a and IgG2b with the same specificity to induce IgG subclass-specific anaphylaxis, we found that IgG1 and IgG2b-PSA shared a common mechanism that involved all tested myeloid cells and in which histamine H1 receptor blockade showed a stronger beneficial effect on PSA-associated temperature drop than PAF receptor blockade (2). IgG1- and IgG2b-PSA were regulated by the inhibitory IgG receptor FcγRIIB present on all myeloid cells and B cells. In contrast in IgG2a-PSA, FcγRIIB-driven inhibition was negligible. IgG2a-PSA was significantly reduced through depletion of neutrophils or monocytes/macrophages and attenuated by both PAF-receptor and histamine H1 receptor antagonists (2). This particularity of IgG2a-PSA may be due to the overall higher affinity of IgG2a to FcγRs (2) that also may explain the relative resistance of IgG2a-PSA to changes in IgG/FcγR affinity induced by modification of IgG-glycosylation (i.e. terminal sialylation) compared to IgG1/IgG2b-PSA (4).

IgG-anaphylaxis in FcγR-humanized mice

To approach human pathophysiology, anaphylaxis has been studied in mice carrying human FcγRs, either as a single transgene, as in the case of hFcγRIIA (5-7), or in more complex models expressing several FcγRs (6). Indeed, extrapolating results from IgG/FcγR-dependent reactions from mouse to human pathophysiology is challenging, because both species express very different sets of FcγRs (four in mice, six in humans) that each shows distinct interaction profile with the different IgG subclasses (IgG1-4 in human). Among human FcγRs, only FcγRIIB is inhibitory and expressed at much lower levels than in mice, suggesting that regulation of IgG-driven responses in humans though co-engagement of this

inhibitory receptor is less effective than in mice. Furthermore, as an example, whereas IgG3 binds to all human FcγRs, its murine counterpart exclusively engages mouse FcγRI. These differences extend through all IgG subclasses, their affinities for FcγRs and their capacity to trigger Fc-dependent effector functions. Studies in FcγR-humanized mice revealed that engagement of human FcγRs by IgG-ICs is sufficient to trigger anaphylaxis (5). Among hFcγRs, hFcγRIIA appears to be the major contributor in IgG-PSA (6) and despite its expression on all myeloid cells, hFcγRIIA-expressing neutrophils and monocytes/macrophages, through their release of PAF, play a predominant role over mast cells, basophils and eosinophils (5). Unexpectedly, hFcγRIIA-transgenic mice also revealed the critical contribution of a blood component that was until then overlooked in the context of anaphylaxis.

Role of platelets in IgG-anaphylaxis

Mouse platelets are devoid of any FcγR. Human platelets on the contrary express FcγRIIA/CD32A and incubation with IgG-ICs can induce their activation, aggregation and release of granular content. Using hFcγRIIA-transgenic mice that confer IgG receptor expression to platelets, we and others demonstrated that IgG-induced platelet activation is critical for experimental anaphylaxis, and results in a rapid, severe and prolonged (24 h) thrombocytopenia (6, 7). Activated platelets released serotonin, which determined the severity of anaphylaxis (6, 7). Platelets also contributed to IgG-PSA in a more complex mouse model of cognate hFcγR expression (6). Recently, platelet-released PAF was similarly proposed to trigger a transient disruption of endothelial integrity and mast cell activation resulting in shock (8). Due to their abundance in blood, it is therefore conceivable that platelets are among the first players to become activated by circulating IgG-ICs triggering a cascade of events that drives the activation and mediator release from various cell types contributing to anaphylaxis (Figure 2).

Relevance for human anaphylaxis and conclusion

The fact that transgenic expression of a complete set of human FcγRs reproducing mostly the original expression profiles on all hematopoietic cells stimulated with human aggregated IgG is sufficient to induce anaphylaxis in mice (6), is a strong indicator for the relevance of IgG anaphylaxis in humans. Indeed, several lines of evidence support the existence of IgG/FcγR-, neutrophil- and PAF-dependent human anaphylaxis. Cases of

anaphylaxis were reported after administration of different therapeutic IgG antibodies (1), and serum PAF concentrations correlate with anaphylaxis severity in humans (9). In a clinical study of neuromuscular-blocking agent-induced anaphylaxis, concentrations of anti-drug IgG, markers of FcγR engagement and neutrophil activation (upregulation of CD11b and CD18, elevated levels of elastase and DNA-MPO complexes in plasma), as well as reduced activity of PAF-acetyl hydrolase correlated with anaphylaxis severity (10). Notably, neutrophil activation could be observed in patients lacking evidence of classical IgE-anaphylaxis (10). Limited data from these patients further evidenced that platelet activation (upregulation of CD62P) was associated with anaphylaxis severity and that anaphylaxis occurrence was accompanied by a reduction in circulating platelet numbers (6). These findings open new perspectives for the understanding and management of IgE-independent anaphylaxis in humans. In addition to certain drugs that can directly activate mast cells (notably through the recently described MRGPRX2), IgG-dependent reactions may account for or contribute to anaphylaxis, in particular when large amounts of IgG-ICs can form in the circulation. Further clinical studies will allow to determine whether it could be beneficial for patients at risk of developing IgG-driven anaphylaxis (i.e. programmed intravenous administration of certain antibodies or drugs) to transiently receive treatments to block FcγRs (especially FcγRIIA) or limit the biological effects of serotonin and/or PAF.

Author Contributions

All authors have made a substantial intellectual contribution to the manuscript, and approved it for publication.

Acknowledgements

We are grateful to all collaborators that over the years contributed to work discussed in this manuscript. Some of the work mentioned in this article has been supported by a Jeunes Chercheuses/Jeunes Chercheurs grant from the Agence National de la Recherche (ANR-16-CE15-0012-01) and a subvention by the French Society of Allergology (SFA). FJ is an employee of CNRS (Centre national de la recherche scientifique).

References

1. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. *J Allergy Clin Immunol.* 2017;140(2):335-48.

2. Beutier H, Gillis CM, Iannascoli B, Godon O, England P, Sibilano R, et al. IgG subclasses determine pathways of anaphylaxis in mice. *J Allergy Clin Immunol.* 2017;139(1):269-80 e7.
3. Khodoun MV, Kucuk ZY, Strait RT, Krishnamurthy D, Janek K, Clay CD, et al. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis. *J Allergy Clin Immunol.* 2013;132(6):1375-87.
4. Epp A, Hobusch J, Bartsch YC, Petry J, Lilienthal GM, Koeleman CAM, et al. Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions. *J Allergy Clin Immunol.* 2018;141(1):399-402 e8.
5. Jonsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. *Blood.* 2012;119(11):2533-44.
6. Beutier H, Hechler B, Godon O, Wang Y, Gillis CM, de Chaisemartin L, et al. Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. *Sci Immunol.* 2018;3(22).
7. Cloutier N, Allaey I, Marcoux G, Machlus KR, Mailhot B, Zufferey A, et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. *Proc Natl Acad Sci U S A.* 2018;115(7):E1550-E9.
8. Karhausen J, Choi HW, Maddipati KR, Mathew JP, Ma Q, Boulaftali Y, et al. Platelets trigger perivascular mast cell degranulation to cause inflammatory responses and tissue injury. *Sci Adv.* 2020;6(12):eaay6314.
9. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol.* 2013;131(1):144-9.
10. Jonsson F, de Chaisemartin L, Granger V, Gouel-Cheron A, Gillis CM, Zhu Q, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. *Sci Transl Med.* 2019;11(500).

Figure Legends:

Figure 1. Pathophysiologic changes in experimental anaphylaxis in mice. Anaphylaxis is a systemic hypersensitivity reaction that affects multiple organs; the most common clinical signs of anaphylaxis in mice are indicated. Created with BioRender.com

Figure 2. Model of IgG-dependent experimental anaphylaxis in hFcγRIIA-expressing mice in the absence of mouse endogenous FcγRs. Human FcγRIIA expression is conserved in hFcγRIIA-transgenic mice, including its expression on all myeloid cells and platelets. Injected heat-aggregated (HA)-IgG, mimicking IgG-ICs forming inside the circulation, can engage hFcγRIIA on any of these cells, but will have a stochastically higher likelihood to encounter platelets>neutrophils>monocytes>>basophils, leading to their activation. As a consequence platelets will be activated, form aggregates, adhere to circulating leukocytes and degranulate. Platelet-released serotonin can directly trigger anaphylaxis-associated vascular leakage, vasodilation and bronchoconstriction. Platelet-released PAF, or PAF-release by other IgG-IC-activated myeloid cells can fuel the reaction through activation of perivascular mast cells

223 leading to histamine release. PAF and histamine may contribute to clinical signs of hFcγRIIA
224 -PSA in mice. Created with BioRender.com